During the past decade, UOC Malattie Infettive, ASST Papa Giovanni XXIII conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "UOC Malattie Infettive, ASST Papa Giovanni XXIII" are "COVID-19" (2 trials). Many other conditions were trialed in "UOC Malattie Infettive, ASST Papa Giovanni XXIII" in a lesser frequency.

Most popular intervention types in "UOC Malattie Infettive, ASST Papa Giovanni XXIII" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Remdesivir" (2 trials) and "Standard of Care" (2 trials). Other intervention names were less common.

The vast majority of trials in "UOC Malattie Infettive, ASST Papa Giovanni XXIII" are 2 trials for "All" genders.

Currently, there are NaN active trials in "UOC Malattie Infettive, ASST Papa Giovanni XXIII". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in UOC Malattie Infettive, ASST Papa Giovanni XXIII, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in UOC Malattie Infettive, ASST Papa Giovanni XXIII, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".